Antagonist anti-cd40 monoclonal antibody therapy for...

Details Antagonist anti-cd40 monoclonal antibody therapy for... Antagonist anti-cd40 monoclonal antibody therapy for...

A - Human Necessities

61

K

A61K 38/19 (2006.01) A61K 39/395 (2006.01) C07K 14/52 (2006.01) C07K 16/28 (2006.01)

Patent

CA 2466931

The present invention is directed to a method for preventing or alleviating the symptons of MS by delivering to the central nervous system an interferon and an anti-CD40 antibody. Interferons include interferon-.beta. and its muteins such as IFN-.beta.ser17.

L'invention concerne une méthode permettant de prévenir ou d'atténuer les symptômes de la sclérose en plaques par l'administration au système nerveux central d'un interféron et d'un anticorps anti-CD40. Les interférons comprennent l'interféron-.beta. et ses mutéines, telles que l'IFN-.beta.¿ser17?.

Affiliated with

Also associated with

Rating

Antagonist anti-cd40 monoclonal antibody therapy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonist anti-cd40 monoclonal antibody therapy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonist anti-cd40 monoclonal antibody therapy for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1439024